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Significant advances in transcriptional reg-
ulation of gene expression, coupled with
the development of transgenic animals,
have provided whole-animal systems where
the mammary gland is of special interest
for experimental (1) and therapeutic appli-
cations (2). The characterization of mam-
mary-specific promoter sequences in milk
protein genes has been of critical impor-
tance to investigating induction of onco-
gene expression (3,4) and stimulation of
cell proliferation by growth factors (5) in
mammary tissue. As a consequence of this
progress, the mammary gland of experi-
mental animals has been genetically engi-
neered to explore the molecular mecha-
nisms involved in the development of
mammary neoplasia. Furthermore, trans-
genic approaches have been developed for
modifying the mammary gland to produce
heterologous proteins of pharmaceutical
and industrial interest (6).
This article presents some ofthe recent
research advances that define the develop-
mental and hormonal control ofexpression
of mammary-specific promoters and the
use ofthese regulatory regions in directing
the production ofheterologous proteins in
milk oftransgenic animals. We attempt to
complement earlier reviews (7,8) and criti-
cally integrate important aspects of the
physiology of the mammary gland with
recent observations pertaining to regula-
tion of gene expression of milk protein
genes. Finally, we discuss the advantages of
manipulating the genetic makeup ofmam-
mary tissue, as well as the pitfalls and
potential areas of concern associated with
bioengineering the mammary gland.
Development ofthe Mammary
Gland: Growth and Differentiation
The development ofthe mammary gland is
brought about by proliferative and differ-
entiative events that begin during embryo-
genesis and progress into the lactating state
(9,10). At birth, the mammary gland is a
rudimental branched-duct system that
develops isometrically with the rest of the
body. With the onset of puberty, ovarian
hormones initiate ductal morphogenesis
through cycles of mammary cell prolifera-
tion that result in branching of the duct
system and fat deposition (11). With preg-
nancy, the secretory cells ofthe ductal tree
enter a phase ofsustained proliferation that
continues during early lactation, leading to
complete lobulo-alveolar development.
This process (mammogenesis) is largely
responsible for most of the volumetric
development ofmammary tissue.
Lactogenesis, the capacity for mamma-
ry tissue to synthesize and secrete milk, is
made possible because the mammary gland
is a specialized organ that secretes milk
components into the lumen of ducts.
Embedded in a stromal milieu, alveoli are
the working units ofthis branched-glandu-
lar machinery. In vitro, alveolarlike struc-
tures, generally referred to as mammo-
spheres (12), can be generated by culturing
mammary epithelial cells on components
of the extra cellular matrix (Fig. 1) (13).
Histological cross-sections of fully devel-
oped mammospheres show alveolar mor-
phology characteristic of columnar-shaped
epithelial cells that delineate a hollow
sphere where milk components are secreted
by exocytosis (14).
Proliferation and differentiation of the
mammary gland are controlled by a large
number of factors that include various
steroids, peptide hormones, and growth
factors. Endocrine control of mammary
development is not only species specific,
but also differs in prepubertal growth when
compared to pregnancy and lactation.
Early studies (15-17) which used ablation
ofendocrine glands and replacement thera-
py techniques in rats and mice, provided
evidence that mammary development is
under the control of the ovarian steroids,
estrogen and progesterone. Specifically,
during the prepubertal stage, replacement
therapy with estrogen, in combination
with either growth hormone or prolactin,
stimulates ductal growth, which is
enhanced further by glucocorticoids.
Lobuloalveolar growth in ovariectomized,
hypophysectomized, and adrenalectomized
mice required replacement therapy with
both progesterone and estrogen in addition
to growth hormone or prolactin.
The contribution to mammary devel-
opment by peptide hormones is also well
documented. For example, insulinlike
growth factor-I (IGF-I), primarily pro-
duced in the liver, mediates growth hor-
mone actions on mammary tissue through
an endocrine mode of action. In addition,
experimental evidence (18,19) suggests
that growth factors, such as IGF-I and epi-
dermal growth factor (EGF) may act local-
ly through autocrine/paracrine pathways.
Taken together, these observations offer
compelling evidence that several biochemi-
cal messengers act coordinately to control
morphogenesis and biochemical differenti-
ation of mammary cells necessary for the
synthesis and secretion of milk compo-
nents (20).
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Regulation ofExpression ofMilk
Protein Genes and Characterization
ofMammary-specific Elements
Approximately 90% ofthe protein in milk
of dairy species is accounted for by four
caseins (asl, as2, P, and K), and two whey
proteins (a-lactalbumin and P-lactoglobu-
lin). In rodents, the whey acidic protein
(WAP) is the major whey protein (6).
Expression of milk protein genes is under
the control of various factors that include
steroids, peptide hormones, and cell-sub-
tratum interactions and requires well-
defined stage-dependent conditions.
Although the development of alveolarlike
structures begins in mid-gestation, the
expression ofmilk proteins is minimal prior
to birth. The onset of lactation coincides
with a marked decrease in serum proges-
terone, which is inhibitory to the galac-
topoietic pathways (21), and an elevation of
circulating lactogenic hormones, primarily
glucocorticoids and prolactin (22).
Full differentiation requires morpholog-
ical changes that are triggered by the estab-
lishment of cell-cell contacts. These inter-
actions are necessary for mammary epithe-
lial cells to assume correct cellular polarity
and form a luminal compartment. In fact,
the presence ofspecific extracellular matrix
components induces the formation oflobu-
lo-alveolar structures and promotes coordi-
natelywith lactogenic hormones the expres-
sion ofmilk protein genes (23).
Induction ofexpression ofmilk protein
genes is mediated through activation of
hormone responsive elements (HRE) local-
ized in 5' flanking promoter regions. A
variety of promoter elements have been
characterized that direct the expression of
the oc-casein (24), ,-casein (25), a-lactal-
bumin (26), f-lactoglobulin (27), and
WAP (28) genes. Interestingly, the a- and
,B-casein genes have most likely evolved
from a common ancestor gene and the 5'
flanking region of both genes contains
putative HRE sequences that are highly
conserved. The evolutionary conservation
ofthe HRE element is ofgreat importance
to mammary gland biotechnologists; in
fact, the characterization of "universal"
transcription regulatory sequences may
allow for their general use in different
species. For example, various 5' flanking
sequences of the mouse WAP gene have
been used successfully to direct the expres-
sion ofthe human protein C in transgenic
pigs (29).
Bioengineering the mammary gland
requires that transcription modules de-
signed to drive the expression of heterolo-
gous proteins should be mammary specific
and under the same developmental and
hormonal constraints that regulate the
expression of endogenous milk protein
Figure 1. Formation of mammospheres by mammary epithelial cells. Mammary epithelial cells MD-IGF-I
(13) were plated on extracellular matrix derived from the Engelbreth-Holm-Swarm tumor and cultured in
the presence of lactogenic hormones. After 72 hr cells organized into alveolarlike structures that mim-
icked the phenotype characteristic ofdifferentiated cells in vivo.
genes. This is the case of the glucocorti-
coid-inducible mouse mammary tumor
virus-long terminal repeat (MMTV-LTR)
promoter element, which is primarily
active in the mammary gland. Although it
may sustain the expression ofheterologous
proteins in other tissues (30), the MMTV-
LTR contains sequences that are the target
for binding not only by glucocorticoid but
also sex steroid and mineralocorticoid
receptors (31). Consequently, the LTR ele-
ment has been used extensively to direct
transgene expression in intact animals and
cell culture of growth factors and proto-
oncogenes that may be involved in the
development of mammary neoplasia (32).
Conversely, lack of mammary specificity
could lead to deregulated activation of a
transgene in different tissues and impair
the normal physiology of the whole ani-
mal. Constitutive, tissue nonspecific
expression oftransgenes would be expected
ifthe transgenes were under the control of
strong constitutively active transcriptional
elements, such as those found in the simi-
an SV40 or herpes simplex thymidine
kinase (TK) promoters (33).
Regulation ofExpression of
Transgenes
The random integration ofchimeric genes
into the genome ofthe host cell may abro-
gate the correct position-independent
expression of heterologous proteins, lead-
ing to lack of mammary gland specificity.
Many studies have demonstrated that tis-
sue-specific expression of 5' flanking
regions of the WAP gene was copy-num-
ber independent and highly affected by the
site of integration (6). Moreover, experi-
mental evidence suggests that site-depen-
dent regulation of expression may occur
because of the structural organization of
the heterochromatin surrounding the inte-
grated transgene (34). This nuclear envi-
ronment may in turn affect the regulation
oftranscription ofheterologous genes neg-
atively or positively.
Ideally, each integration event should
express the same level ofactivity in a domi-
nantlike fashion. Site integration-indepen-
dent expression may be achieved if a
defined transcriptional module could be
topologically protected from effects of the
surrounding genetic material. Notably, in
search of DNA modules that may confer
position-independent expression to trans-
genes, significant progress has been made
in defining cis-acting matrix attachment
regions (MAR). The MAR elements have
been located in border regions oftranscrip-
tionally active DNA domains of the
human ,-globin (34) and chicken
lysozyme (35) genes and shown to possess
high binding affinity for nuclear matrix
molecules (36). Specifically, strong attach-
ment regions were located between 11.1
and 8.8 kb upstream of the transcription
start site and between 1.3 and 5.0 kb
downstream of the poly(A)+ site of the
chicken lysozyme (35). The use of one
such MAR region, the A element (A =
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Figure 2. Expression of transgenes in mammary epithelial cells. (A)
Structural organization of the mouse mammary tumor virus (MMTV) DNA
provirus. The integrated DNA is composed of the structural genes gag,
pol, and env coding, respectively, for antigen proteins, RNA-dependent
DNA polymerase, and the envelope protein. The structural genes are
flanked on both sides with long-terminal repeats (LTR). (B) Schematic
representation of a mammary-specific expression construct. Matrix
attachment regions (MAR) can confer position-independent and high-level
expression of randomly integrated transgenes (36); P, promoter region;
TCS,transgene-coding sequence (cDNA or genomic).
Figure 3. Expression of human therapeutic proteins in the mammary gland.
(A) Regulation of expression of human cx1-antitrypsin (AT) under control of
the f-lactoglobulin promoter (27). (B) Whey acidic protein (WAP) gene
drives expression of a 1.6-kb human protein C (hPC) cDNA (29). (C)
Expression of human lactoferrin (hLF) under the control of the bovine aos
promoter and 3' flanking regions (62).
attachment), in WAP expression vectors
confers position-independent, as well as
hormonally and developmentally correct,
regulation ofexpression in transgenic mice
(32).These studies provided significant evi-
dence of the ability of chicken lysozyme
MAR sequences to serve as structural cis-
acting elements that confer position-inde-
pendent and high level expression of ran-
domly integrated transgenes.
It should be pointed out that this strat-
egy presents interesting similarities with
that used by the MMTV during its infec-
tious cycle in the mammary gland. The
integrated DNA provirus of the MMTV
consists of three structural genes (gag, poc
and env), which are flanked on both sides
by two LTRs (Fig. 2). Activity of the two
LTR elements is position independent and
primarily under control ofthe trans-acting
glucocorticoid-hormone receptor complex
(38). These are peculiar structural features
of the replicating strategy of the MMTV
that may offer significant hints to biotech-
nologists in their effort to manipulate the
expression of transgenes in mammary
epithelial cells.
The expression of heterologous pro-
teins in milk of transgenic animals has
been commonly targeted by cloning
cDNAs that encode for the protein of
interest in-frame with 5' DNA fragments
that contained defined transcription units.
However, this strategy has not always been
successful in attaining high expression lev-
els due to absence in the expression vector
of essential cis-acting regulatory sequences.
The inclusion of additional 5' DNA
domains and 3' untranslated regions and
use of genomic clones or minigenes have
conferred enhanced and proper hormonal
regulation of expression of chimeric con-
structs (Table 1). We can speculate that a
foreign DNA sequence may be correctly
transcribed, although integrated in the
extraneous genomic material of the host
cell, provided that 1) the transgene is with-
in the context ofits regulon that contains a
dominant locus control region (LCR) sen-
sitive to differentiative signals (36), and 2)
the expression construct carries sufficient
sequence information to assure appropriate
developmental and hormonal regulation of
expression. The use of MAR- and LCR-
based expression vectors may prevent loss
of expression if a transgene integrates in a
silent region and lack of hormonal regula-
tion due to influence of negative or posi-
tive neighboring cis-acting control ele-
ments.
Trans-actingRegulation ofExpression
An additional level of regulation is repre-
sented by interactions of regulatory se-
quences with trans-acting mammary cell-
specific nuclear factors. This aspect should
be taken into consideration when choosing
a particular promoter element to direct the
expression of heterologous proteins. It is
instructive to consider that a 0.4-kb pro-
moter element ofthe sheep f-lactoglobulin
gene contains binding sites for both the
nuclear factor I (NFI) and milk protein
binding factor (MPBF). As expected, both
factors affected the transcriptional activity
of the P-lactoglobulin promoter in trans-
genic mice (39). Similarly, the hormonal
stimulation by lactogenic hormones of the
bovine and rodent 1-casein genes required
removal of transcriptional repression and
binding to a mammary gland-specific tran-
scription factor (MGF) (40). The presence
of binding sites in the 5' region of the
MMTV-LTR for the mammary cell-acti-
vating factor (MAF) and transcription fac-
tors of the CTF/NFI family indicates that
activity of the viral LTR element is also
regulated by mammary cell-specific trans-
acting regulators. This is not surprising, as
the MMTV relies on the cellular machin-
ery ofmammary epithelial cells to assemble
retroviral particles and trigger mammary
tumor formation. Of interest is that
homologous binding sites for the MAF and
CTF/NFI nuclear factors are present in the
5' flanking region of the WAP gene nor-
mally expressed only in rodents and rabbits
(41). These observations are in keeping
with evolutionarily conserved molecular
mechanisms that control expression of
milk protein genes in different species.
This knowledge can now be exploited to
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Table 1. Expression of heterologous proteins in the mammary gland underthe control of mammary promoter elements
Transgene
Element Type Clone Transgenic species Accessory regions Expression level/phenotype Reference
7-kb WAP gene WAP Genomic Mouse 3-kb MAR Position independent (36)
5' 2.6-kb WAP htPA cDNA Mouse Position dependent (28)
5' 2-kb,-casein ILK-2 Genomic Rabbit Poly(A) Low (57)
7.2-kb WAP gene WAP Genomic Mouse Site dependent (58)
5' 2.4-kb WAP hGH Genomic Mouse Poly(A) Repressed at birth (59)
7.2-kb WAP gene hPC cDNA Pigs Poly(A) High (29)
5' 0.9-kb WAP WAP Genomic Mouse SV40-poly(A) Deregulated (1)
4-kb f-lactoglobulin gene halcAT Genomic Mouse Poly(A) High (27)
5' 17.6-kb WAP ha1-AT Genomic Mouse High (60)
8.9-kb )-lactoglobulin hFIX cDNA Sheep Low (61)
5' 1.5-kb MMTV hTGFcx cDNA Mouse 3-globin LTR Mammarytumors (32)
5' 1.3-kb MMTV olGF-I cDNA Bovine SV-splice [poly(A) LTR] High (5)
3.3osl-casein hERY Genomic Mouse High (2)
asl-casein gene hLF cDNA Mouse High (62)
5' 2.5-kb WAP c-myc Genomic Mouse - Mammarytumors (4)
5' 2.5-kb WAP Ha-ras Genomic Mouse Mammarytumors (3)
Abbreviations: WAP, whey acidic protein; MAR, matrix attachment region; htPA, human tissue plasminogen activator; ILK-2, interleukin-2; hGH, human growth
hormone; hPC, human protein C; ha1-AT, human cx1-antitrypsin; hFIX, human factor IX; MMTV-LTR, mouse mammary tumor virus-long terminal repeat; olGF-I,
ovine insulinlike growth factor-I; hERY, human erythropoietin; hLF, human lactoferrin.
bioengineer the mammary gland to pro-
duce heterologous proteins.
Bioengineering the Mammary Gland
Bioactivity of many proteins usually
requires post-translational modifications,
such as glycosylation and carboxylation.
These complex modifications may not be
carried out in bacterial systems in such a
way to yield products of desirable biologi-
cal equivalence or potency. As a result,
chemical manipulation of proteins pro-
duced in prokaryotic cells may be needed
before recombinant proteins can be used
for therapeutic or industrial purposes.
Various animal cell culture systems have
been developed since mammalian cells are
equipped with the cellular machinery to
produce fully processed biologically active
peptides. An exciting alternative approach
is provided by the knowledge of mamma-
ry-specific elements and the ability to gen-
erate transgenic animals; scientists now
have the opportunity to target expression
of heterologous proteins to the mammary
gland. Although initial studies focused on
rodent models, the generation of large
transgenic farm animals such as sheep,
pigs, and dairy cows offers the opportunity
for large-scale production of heterologous
proteins in milk.
Emphysema and acx-Antitrypsin.
Emphysema occurs as a consequnce of
destruction of lung parenchyma with
potential reduction of surface area of the
alveolar walls. This pathological state is the
result of excessive proteolytic degradation
of elastin fibers by the protease elastase
released by neutrophils. The condition is
linked to (xr-antitrypsin deficiency. Under
normal conditions the liver produces suffi-
cient quantities ofa1-antitrypsin, which is
present in serum at levels ofapproximately
200 mg/dl. a1-Antitrypsin exerts its pro-
tective action by complexing with the
enzyme elastase, which prevents unbal-
anced proteolytic breakdown of lung tis-
sue.
Deficiency ofa1-antitrypsin is a hered-
itary disorder resulting from mutations in
the a1-antitrypsin gene located on chro-
mosome 14. In homozygous individuals
with the genotype Piz (Pi = protease
inhibitor, Z = type) arising from a single
base mutation, serum levels of a1-anti-
trypsin drop to about 25 mg/dl. The Piz
mutation afflicts about 1 in 1000 persons
in the United States. Such low levels of
a1-antitrypsin in serum are not sufficient
to protect the respiratory tract from enzy-
matic proteolysis. This leads to chronic
obstructive emphysema and decrease in
longevity (42). Clinical strategies to
counteract lung destruction rely on intra-
venous treatment with a -antitrypsin or
respiratory administration of this protein
in an aerosol form (43).
The bacterium E. coli has been success-
fully engineered to produce ax-antitrypsin.
However, the recombinant molecule is not
equivalently glycosylated compared with the
natural counterpart, and as a result the half-
life in serum ofE coli-derived ac-antitrypsin
is greatly reduced. As normal individuals
produce approximately 2 g/day of a x-anti-
trypsin, large amounts ofplasma are required
to purify sufficient quantities of this protein
for therapeutic use. Therefore, production of
a1-antitrypsin in milk of transgenic animals
may provide an alternative route for large-
scale production of this protein. High-level
expression ofactive human a1-antitrypsin in
milk oftransgenic sheep was first reported in
1991 (44). The genomic sequence oftheal-
antitrypsin gene was under the control ofthe
3-lactoglobulin promoter. Expression levels
ranged from 1 to 60 g/l of milk (Fig. 3A).
Moreover, the cc-antitrypsin purified from
milk appeared fully glycosylated and dis-
played normal biological activity.
Anticoagulants: Protein C. Human
protein C (hPC) is a vitamin-K-dependent
anticoagulant produced in the liver.
Human protein C is an important compo-
nent of one of the many control systems
involved in regulation of hemostasis and
coagulation. Upon damage of epithelia,
hPC proteolytically cleaves in concert with
S-thrombomodulin components of the
coagulation cascade (45) that act as anti-
clotting agents. Human protein C also
blocks the activity of tissue-plasminogen
activator (tPA) inhibitor, which allows tPA
to generate plasmin that in turn lyses clots.
Deficiency ofhPC due to hereditary disor-
ders, liver diseases, or intake of vitamin K
antagonists may lead to hypercoagulating
states. In heterozygous subjects, levels of
circulating hPC are lower than normal (4
mg/ml), whereas protein C deficiency in
homozygous individuals is associated with
thrombosis and death in infants.
Secretion ofhPC in milk oftransgenic
mice and swine has been reported by
Velander et al. (29) (Fig. 3B). In this
study, an hPC cDNA was under the con-
trol ofa 2.6-kb 5' flanking region, and 3.0
kb of coding and 1.6 kb of 3' flanking
sequence of the WAP gene (Table 1).
Transgenic pigs produced up to 1 g/l of
milk ofrecombinant hPC, which displayed
equivalent anticoagulant activity to protein
C purified from human plasma. Given the
low concentration of hPC in normal plas-
ma, production of recombinant protein C
in milk of transgenic animals may prove a
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useful alternative for large-scale supply of
this anticoagulant factor.
Lactoferrin. Lactoferrin, a member of
the transferrin family, is one of the pre-
dominant whey proteins in milk. The iron-
binding capacity of this protein accounts
for most of the iron present in milk.
Lactoferrin is also a ubiquitous protein in
mammals: it can be found in high quanti-
ties in granules of human polymorphonu-
clear leukocytes and in mucosal and respira-
tory tract secretions. Structurally, lactofer-
rin is glycosylated with two iron-binding
sites at homologous domains (46). Three
primary functions have been speculated for
lactoferrin: first, lactoferrin as a carrier of
iron complements the nutritional value of
milk. The iron-saturated form, however,
accounts for only 5% of the total lactofer-
rin present in milk. Second, the iron-free
lactoferrin, which is the primary form
(95%), has distinct bacteriostatic effects on
growth of gram-negative bacteria (42'. In
association with lyzozyme, lactoferrin is
also bactericidal for strains of V cholerae, S.
typhimurium, and E. coli. In this capacity,
lactoferrin acts by depriving microorgan-
isms ofiron as well as modifying membrane
permeability of bacterial cells. The latter
modification causes damage of the outer
membrane of bacteria species populating
the intestine and therefore increases their
sensitivity to subsequent exposure to bacte-
ricidal substances. Third, lactoferrin dis-
plays anti-inflammatory properties through
a number of mechanisms (4/). Generation
of dairy calves transgenic for the human
lactoferrin fusion gene has been previously
reported (48). In these animals, expression
of a human lactoferrin cDNA was under
the control of 15 kb of the 5' flanking
region and 6 kb of the 3' untranslated
region of the bovine xsl-casein gene (Fig.
3C). In addition, regulatory sequences of
the bovine axsl-casein gene allowed expres-
sion ofhuman lactoferrin in milk of trans-
genic mice (49), up to 36 mg/ml. The
recombinant lactoferrin appeared to have
an identical molecular mass and immuno-
reactivity when compared with lactoferrin
derived from human milk.
Future Developments, Animal
Welfare, and Potential Pitfalls
Genetic engineering of the mammary
gland is the result ofprogress in several sci-
entific disciplines, including mammary
gland biology, embryo transfer, and molec-
ular biology (50). Bioengineering of the
mammary gland to produce pharmaceuti-
cal proteins may be regarded as an effective
strategy to manipulate the physiology of
the mammary gland of farm animals to
enhance human welfare. Conceptually,
bioengineering of the mammary gland
could complement traditional strategies of
genetic breeding designed to increase fre-
quencies of traits of interest in farm ani-
mals. Nevertheless, because farm species
are an integral component of the natural
ecologic system and human microenviron-
ment, the manipulation of the genetic
makeup of the mammary gland may be of
concern. For example, ectopic expression
of heterologous proteins may affect the
health of transgenic animals. Secretion of
tPA in goats' and WAP in pigs' milk,
respectively, was associated with lactational
shutdown immediately after parturition
(51). Similarly, in transgenic mice, overex-
pression of transforming growth factor-oc
under the control ofthe MMTV promoter
caused failure of lactation due to lack of
elevation of mammary prolactin receptors
after parturition (52). Also, expression of
a1-antitrypsin in the salivary glands of
transgenic mice was reported when an ax-
antitrypsin minigene was under the control
of a 5' flanking region of the ovine f-lac-
toglobulin gene (27).
It is also important to question whether
treatment of human subjects with recom-
binant milk-derived proteins may cause
undesirable side effects. In fact, as recom-
binant proteins produced by mammary
epithelial cells may have biological proper-
ties other than the therapeutic one, poten-
tial secondary effects on human health
should be carefully monitored. Transgenic
approaches to modify the mammary gland
must be economically advantageous. In
this respect, the relatively inefficient E. coli
and mammalian cell culture models may
soon be replaced by yeast systems that may
render bioengineering of the mammary
gland economically inefficient. In this
light, the yeast Pichia pastoris has been
used successfully for high-level expression
of recombinant proteins, such as tumor
necrosis factor (53). Because Pichiapastoris
is a eukaryote, it can perform post transla-
tional modifications similar to those car-
ried out by mammary cells.
In support ofbioengineering the mam-
mary gland, this technology has the poten-
tial for making available large quantities of
proteins that are naturally present at low
concentration in biological fluids. Health
considerations associated with direct
human consumption of milk produced by
transgenic animals appear to be of moder-
ate concern. Milk produced by transgenic
animals would be processed for extraction
and purification of precious therapeutic
proteins. Moreover, protein products pre-
sent in milk may be proteolytically digest-
ed or otherwise altered during ingestion
and therefore become inactive.
Targeting the expression of heterolo-
gous proteins to the mammary gland may
have important imp lcations in environ-
mental health and neonatal toxicology
research (54). Transgenic mammary epi-
thelial cells could provide gene knock-out
models to investigate modulation of
expression in response to environmental
chemicals (55). In this respect, potential
effects of altered human lactation on the
nursing neonate due to maternal exposure
to environmental xenobiotics were the
focus ofa workshop sponsored in 1992 by
the National Institute of Environmental
Health Sciences (56). In conclusion, the
advantages of bioengineering the mamma-
ry gland offarm animals are obvious where
the availability oflarge quantities ofnatur-
al peptides is a limiting factor and milk-
derived proteins of potential therapeutic
and nutritive value could be used success-
fully for the treatment of chronic and
hereditary diseases.
REFERENCES
1. Dale TC, Krnacik MJ, Schmidhauser C, Yang C L-
Q, Bissel MJ, Rosen JM. High-level expression of
the rat whey acidic protein gene is mediated by ele-
ments in the promoter and 3' untranslated region.
Mol Cell Biol 12:905-914 (1992).
2. Janne J, Hyttinen J-M, Peura T, Tolvanen M,
Alhonen L, Halmekyto M. Transgenic animals as
bioproducers of therapeutic proteins. Ann Med
24:112-120 (1992).
3. Andres A-C, Schonenberger C-A, Groner B,
Hennighausen L, LeMeur M, Gerlinger P. Ha-ras
oncogene expression directed by a milk protein
gene promoter: tissue specificity, hormonal regula-
tion, and tumor induction in transgenic mice. Proc
Nad Acad Sci USA84:1299-1303 (1987).
4. Schoenenberger C-A, Zuk A, Groner B, Jones W,
Andres A-C. Induction of the endogenous whey
acidic protein (WAP) gene and a WAP-mychybrid
gene in primary murine mammary organoids. Dev
Biol 139:327-337 (1990).
5. Romagnolo D, Akers RM, Wong EA, Boyle PL,
McFadden TB, Turner JD. Overexpression of
ovine insulin-like growth factor-I stimulates
autonomous autocrine or paracrine growth in
bovine mammary-derived epithelial cells. Mol
Endocrinol 6:1774-1780 (1992).
6. Hennighausen L. The prospects for domesticating
milk protein genes. J Cell Biochem 49:325-332
(1992).
7. RosenJM. Milk protein gene structure and expres-
sion. In: The mammary gland (Neville MC, Daniel
CW, eds). NewYork:Plenum, 1987.
8. Clark AJ. Prospects for the genetic engineering of
milk.J Cell Biochem 49:121-127 (1992).
9. Blackburn DG. Lactation: historical patterns and
potential for manipulation. J Dairy Sci 76:3195-
3212 (1993).
10. Topper YJ, Freeman CS. Multiple hormone inter-
actions in the developmental biology ofthe mam-
marygland. Phys Rev60:1049-1106 (1980).
11. Forsyth IA. Mammarydevelopment. Proc Nutr Soc
48:17-22 (1989).
12. Neville MC, Sthal L, Brozo LA, Lowe-Lieber J.
Morphogenesis and secretory activity of mouse
mammarycultures on EHS biomatrix. Protoplasma
163:1-8 (1991).
13. Romagnolo D, Akers RM Wong EA, Boyle PL,
McFadden TB, Byatt JC, Turner JD. Lactogenic
hormones and extracellular matrix regulate expres-
sion ofIGF-1 linked to MMTV-LTR in mammary
epithelial cells. Mol Cell Endocrinol 96:147-157
(1993).
850 Environmental Health Perspectives0 weir.-Ure-i i.. I
14. Nicherson SC, Akers RM. Biochemical and ultra-
structural aspects of milk synthesis and secretion.
IntJ Biochem 16:855-865 (1984).
15. Cowie AT. The relative growth of the mammary
glands in normal, gonadectomized, and adrenalec-
tomized rats. J Endocrinol 6:147-157 (1949).
16. Lyons WR. The direct mammotrophic action of
lactogenic hormone. Proc Soc Exp Biol Med
51:308-311 (1942).
17. Nandi S. Endocrine control of mammary-gland
development and function in the C3H/He Crgl
mouse.J Natl Cancer Inst 21:1039-1063 (1958).
18. Wilde CJ, Knight CH, Addey CVP, Blatchford
DR, Travers M, Bennett CN, Peaker M. Autocrine
regulation of mammary cell differentiation.
Protoplasma 159:112-1 17 (1990).
19. Brown CF, Teng CT, Pentecost BT, DiAugustine
RP. Epidermal growth factor precursor in mouse
lactating mammary gland alveolar cells. Mol
Endocrinol 3:1077-1083 (1989).
20. Akers, RM. Lactation physiology: a ruminant ani-
mal perspective. Protoplasma 159:96-111 (1990).
21. Shamay A, Zeelon E, Ghez Z, Cohen N,
Mackinlay G, Gertler A. Inhibition of casein and
fat synthesis and at-lactalbumin secretion by proges-
terone in explants from bovine lactating mammary
glands. J Endocrinol 113:81-88 (1987).
22. Streuli CH, Bailey N, Bissell MJ. Control ofmam-
mary epithelial differentiation: basement membrane
induces tissue-specific gene expression in the
absence of cell-cell interaction and morphological
polarity.J Cell Biol 115:1383-1395 (1991).
23. Eisenstein RS, Rosen JM. Both cell substratum reg-
ulation and hormonal regulation of milk protein
gene expression are exerted primarily at the post-
transcriptional level. Mol Cell Biol 8:3183-3190
(1988).
24. Meade H, Gates L, Lacy E, Lonberg N. Bovine
czsl-casein gene sequences direct high level expres-
sion of active human urokinase in mouse milk.
Biotechnology 8:443-446 (1990).
25. Greenberg NM, Anderson JW, Hsueh AJ,
Nishimori K, Reeves JJ, DeAvilla DM, Ward DN,
Rosen JM. Expression of biologically active het-
erodiremic bovine follicle-stimulating hormone in
milk of transgenic mice. Proc Nail Acad Sci USA
88:8327-8331 (1991).
26. Stinnakre MG, Vilotte JL, Soulier S, L'Haridon R,
Charlier M, Gaye P, MercierJC. The bovine at-lac-
talbumin promoter directs expression ofbovine tro-
phoblast interferon in the mammary gland oftrans-
genic mice. FEBS Lett 284:19-22 (1991).
27. Archibald AL, McClenaghan M, Hornsey V,
Simons JP, Clark AJ. High-level expression ofbio-
logically active human cx1-antitrypsin in the milkof
transgenic mice. Proc Natl Acad Sci USA 87:
5178-5182 (1990).
28. Pittius CW, Sankaran L, TopperYJ, Hennighausen
L. Comparison ofthe regulation ofthe whey acidic
protein gene with that ofa hybrid gene containing
thewheyacidic protein gene promoter in transgenic
mice. Mol Endocrinol 2:1027-1032 (1988).
29. Velander WH, Johnson JL, Page RL, Russel CG,
Subramanian A, Wilkins TD, Gwazdauskas FC,
Pittius C, Drohan WN. High-level expression ofa
heterologous protein in the milkoftransgenic swine
using the cDNA encoding human protein C. Proc
NailAcad Sci USA89:12003-12007 (1992).
30. Treamblay PJ, Pothier F, Hoang T, Treamblay G,
Brownstein S, Liszauer A, Jolicoeur P. Transgenic
mice carrying the mouse mammary tumor virus ras
fusion gene: distinct effects in various tissues. Mol
Cell Biol 9:854-859 (1989).
31. Ham J, Thompson A, Needham M, Webb P.
Parker M. Characterization ofresponse elements for
androgens, glucocorticoids, and progestins in
mouse mammary tumor virus. Nucl Acids Res
16:5263-5276 (1988).
32. Matsui Y, Halter SA, Holt JT, Hogan BLM,
Coffey RJ. Development of mammary hyperplasia
and neoplasia in MMTV-TGFat transgenic mice.
Cell61:1147-1155 (1990).
33. Romagnolo D, Akers RM, Byatt JC, Wong EA,
Turner JD. Regulation of expression of IGF-I-
induced IGFBP-3 and IGF-I-receptor by constitu-
tive vsregulated expression ofrecombinant IGF-I in
transfected mammary epithelial cells. Endocrine J
2:375-384 (1994).
34. Grosveld F, van Assendelft GB, Greaves DR,
Kollias G. Position-independent, high-level expres-
sion of the human ,-globin gene in transgenic
mice. Cell 51:975-985 (1987).
35. Phi-Van L, Stratling WH. The matrix attachment
regions ofthe chicken lysozyme gene co-map with
the boundaries of the chromatin domain. Cell
51:975-985 (1987).
36. Bonifer C, Hecht A, Saueressing H, Winter DM,
Sipppel AE. Dyniamic chromatin: the regulatory
domain organization ofeukaryotic gene loci. J Cell
Biochem 47:99-108 (1991).
37. McKnight, Shamay A, Sankaran L, Wall RJ,
Hennighausen L. Matrix-attachment regions can
impart position-independent regulation of a tissue-
specific gene in transgenic mice. Proc Natl Acad Sci
USA 89:6943-6947 (1992).
38. Salmons B, Gunzurg WH. Current perspectives in
the biology of the mouse mammary tumor virus.
Virus Res 8:81-102 (1987).
39. Watson CJ, Gordon KE, Robertson M, Clark AJ.
Interaction of DNA-binding proteins with a milk
protein gene promoter in vitro; identification of a
mammary gland-specific factor. Nucl Acids Res
19:6603-6610 (1991).
40. Wakao H, Schmitt-Ney M, Groner B. Mammary
gland-specific nuclear factor is present in lactating
rodent and bovine mammary tissue and composed
of a single polypeptide of 89 kDa. J Biol Chem
267:16365-16370 (1992).
41. Mink S, Hartig E, Jennewein P, Doppler W, Cato
ACB. A mammary cell-specific enhancer in mouLse
mammary tumor virus DNA is composed ofmulti-
ple regulatory elements including binding sites for
CTF/NFI and a novel transcription factor, mam-
mary cell-activating factor. Mol Cell Biol
12:4906-4918 (1992).
42. Ingram RH Jr, Davies S. Chronic obstructive dis-
eases ofthelung. SciAm Med 3:1-23 (1992).
43. Hubbard RC, Casolaro MA, Mitchell M, Sellers
SE, Arabia F, Matthay MA, Crystal RG. Fate of
aerosolized recombinant DNA-produced xl-anti-
trypsin: use ofthe epithelial surface ofthe lower res-
piratory tract to administer proteins of therapeutic
importance. Proc Nad Acad Sci USA 86:680-684
(1989).
44. Wright G, Carver A, Cottom D, Reeves D, Scott
A, Simons P, Wilmut I, Garner I, Colman A. High
level expression ofactive human alpha-1-antitrypsin
in the milk of transgenic sheep. Biotechnology
9:830-834 (1991).
45. Schrier SL. Disorders of hemostasis and coagula-
tion. Sci Am Med3:1-60 (1993).
46. Anderson BF, Baker HM, Norris GE, Rice DW,
Baker EN. Structure of human lactoferrin; crystal-
lographic structure analysis and refinement at 2.8
angstrom resolution. J Mol Biol 209:711-734
(1989).
47. Ellison RT III, Giehl T. Killing of Gram-negative
bacteria by lactoferrin and lysozyme. J Clin Invest
88:1080-1091 (1991).
48. Krimpenfort P, Rademakers A, Eyestone W, van
der Schans A, van den Broek 5, Kooiman E,
Platenburg G, Pieper F, Strijker R, de Boer H.
Generation oftransgenic dairy cattle using 'in vitro'
embryo production. Biotechnology 9:844-847
(1991).
49. Platenburg GJ, Kootwijk EPA, Kooiman PM,
Woloshuk SL, Nuijens JH, Krimpenfort PJA,
pieper FR, de Boer HA, Strijker R. Expression of
human lactoferrin in milk of transgenic mice.
Transgenic Res (in press).
50. Wall RJ, Hawk HW, Nel N. Making transgenic
livestock: genetic engineering on a large scale. J
Cell Biochem 49:113-120 (1992).
51. Ebert KM, SchindlerJES. Transgenic farm animals:
progress report. Theriogenology 39:121-135
(1993).
52. Sakai S, Mizuno M, Harigaya T, Yamamoto K,
Mori T, Coffey RJ, Nagasawa H. Cause offailure
of lactation in mouse mammary tumor
virus/human transforming growth factor alpha
transgenic mice. Proc Soc Exp Biol Med
205:236-242 (1994).
53. Sreekrishna K, Nelles L, Potenz R, Cruze J,
Mazzaferro P, Fish W, Fuke M, Holden K, Phelps
D, Wood P, Parker K. High-level expression,
purification, and characterization of recombinant
human tumor necrosis factor synthesized in the
methylotrophic yeast Pichia pastoris. Biochemistry
28:4117-4125 (1989).
54. Romagnolo D, DiAugustine RP. The mammary
gland: protein factory ofthe future. Environ Health
Perspect 102:640-642 (1994).
55. Eddy M. The use of transgenic mice for environ-
mental health research. Environ Health Perspect
101:229-300 (1993).
56. Kari FW. Workshop on the effects ofenvironmen-
tal chemicals on lactation and the nursing neonate:
executive summary. National Institute of
Environmental Health Sciences, Research Triangle
Park, NC, 1-3 March 1992.
57. BuhlerThA, Bruyere Th, Went DF, Stranzinger G,
Burki K. Rabbit [-casein promoter directs secretion
ofhuman interleukin-2 into the milk oftransgenic
rabbits. Biotechnology 8:140-143 (1990).
58. Burdon T, Sankaran L, Wall RJ, Spencer M,
Hennighausen. Expression ofa whey acidic protein
transgene during mammary development. J Biol
Chem266:6909-6914 (1991).
59. Gunzburg WH, Salmons B, Zimmerman B,
Muller M, Erfle V, Brem G. A mammary specific
promoter directs expression ofgrowth hormone not
only to the mammary gland, but also to Bergman
glia cells in transgenic mice. Mol Endocrinol
5:123-128 (1991).
60. Bischoff R, Degryse E, Perraud F, Dalemans W,
Ali-Hadij D, Thepot D, Devinoy E, Houdebine L-
M, Pavirani A. A 17.6 kbp region located upstream
ofthe rabbit WAP gene directs high level expression
ofa functional human protein variant in transgenic
mouse milk. FEBS Lett 305:265-268 (1992).
61. Clark AJ, Bessos H, BishopJO, Brown P, Harris S,
Lathe R, McClenaghan M, Prowse C, Simons JP,
Whitelaw CBA, Wilmut I. Expresssion of human
anti-hemophilic factor IX in the milk oftransgenic
sheep. Biotechnology7:487-492 (1989).
62. Strijker, Platenburg G, Nuyens J, Pieper F,
Krimpenfort P, Eyestone W, Rademakers A,
Kootwijk E, Kooiman P, van Veen H, de Boer H.
Expression of human lactoferrin in milk of trans-
genic animals. In: Harnessing biotechnology for
the 21st century (Ladisch MR, Bose A, eds).
Washington, DC:American Chemical Society,
1992;38-41.
Volume 102, Number 10, October 1994 851